Key result
LMWH and other anticoagulants are recommended to prevent VTE in prothrombotic cancer patients.
This review summarizes the pathophysiology and management of cancer-associated thrombosis, emphasizing the role of LMWH in VTE prevention and treatment.
Supports VTE prophylaxis in cancer; hypothesis-generating for optimal agents and duration.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Michael Aschermann (2013) conducted a review in Cancer-associated thrombosis. Anticoagulation (LMWH, UFH, Vitamin K antagonists, fondaparinux) was evaluated. Patients with cancer have a prothrombotic state leading to a higher risk of venous thromboembolism, and prevention with low-molecular-weight heparins or other anticoagulants is recommended.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: